Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 385

1.

Association between Selective Serotonin Reuptake Inhibitor Therapy and Suicidality: Analysis of U.S. Food and Drug Administration Adverse Event Reporting System Data.

Umetsu R, Abe J, Ueda N, Kato Y, Matsui T, Nakayama Y, Kinosada Y, Nakamura M.

Biol Pharm Bull. 2015;38(11):1689-99. doi: 10.1248/bpb.b15-00243.

2.

Heat stroke during treatment with olanzapine, trihexyphenidyl, and trazodone in a patient with schizophrenia.

Lee CP, Chen PJ, Chang CM.

Acta Neuropsychiatr. 2015 Dec;27(6):380-5. doi: 10.1017/neu.2015.29.

PMID:
26503496
3.

Serotonergic medication enhances the association between suicide and sunshine.

Makris GD, Reutfors J, Larsson R, Isacsson G, Ösby U, Ekbom A, Ekselius L, Papadopoulos FC.

J Affect Disord. 2016 Jan 1;189:276-81. doi: 10.1016/j.jad.2015.09.056. Epub 2015 Oct 8.

PMID:
26454332
4.

The association between suicidality and treatment with selective serotonin reuptake inhibitors in older people with major depression: a systematic review.

KoKoAung E, Cavenett S, McArthur A, Aromataris E.

JBI Database System Rev Implement Rep. 2015 Apr 17;13(3):174-205. doi: 10.11124/jbisrir-2015-2272. Review.

PMID:
26447056
5.

Antidepressant prescribing in Irish children: secular trends and international comparison in the context of a safety warning.

O'Sullivan K, Boland F, Reulbach U, Motterlini N, Kelly D, Bennett K, Fahey T.

BMC Pediatr. 2015 Sep 11;15:119. doi: 10.1186/s12887-015-0436-2.

6.

The Beyond Ageing Project Phase 2--a double-blind, selective prevention, randomised, placebo-controlled trial of omega-3 fatty acids and sertraline in an older age cohort at risk for depression: study protocol for a randomized controlled trial.

Cockayne NL, Duffy SL, Bonomally R, English A, Amminger PG, Mackinnon A, Christensen HM, Naismith SL, Hickie IB.

Trials. 2015 Jun 3;16:247. doi: 10.1186/s13063-015-0762-6.

7.

A randomized, double-blind, placebo-controlled study of the efficacy and safety of 2 doses of vortioxetine in adults with major depressive disorder.

Mahableshwarkar AR, Jacobsen PL, Serenko M, Chen Y, Trivedi MH.

J Clin Psychiatry. 2015 May;76(5):583-91. doi: 10.4088/JCP.14m09337.

8.

Safety and tolerability of vortioxetine (15 and 20 mg) in patients with major depressive disorder: results of an open-label, flexible-dose, 52-week extension study.

Jacobsen PL, Harper L, Chrones L, Chan S, Mahableshwarkar AR.

Int Clin Psychopharmacol. 2015 Sep;30(5):255-64. doi: 10.1097/YIC.0000000000000081.

9.

Vitamin C as an adjuvant for treating major depressive disorder and suicidal behavior, a randomized placebo-controlled clinical trial.

Sahraian A, Ghanizadeh A, Kazemeini F.

Trials. 2015 Mar 14;16:94. doi: 10.1186/s13063-015-0609-1.

10.

A multi-site randomized clinical trial to reduce suicidal ideation in suicidal adult outpatients with Major Depressive Disorder: Development of a methodology to enhance safety.

McCall WV, Benca RM, Rosenquist PB, Riley MA, Hodges C, Gubosh B, McCloud L, Newman JC, Case D, Rumble M, Mayo M, White KH, Phillips M, Krystal AD.

Clin Trials. 2015 Jun;12(3):189-98. doi: 10.1177/1740774515573958. Epub 2015 Mar 1.

11.

Clozapine revisited: Impact of clozapine vs olanzapine on health care use by schizophrenia patients on Medicaid.

Thomas KL, Jiang Y, McCombs JS.

Ann Clin Psychiatry. 2015 May;27(2):90-9.

PMID:
25696785
12.

Effects of asenapine in bipolar I patients meeting proxy criteria for moderate-to-severe mixed major depressive episodes: a post hoc analysis.

Berk M, Tiller JW, Zhao J, Yatham LN, Malhi GS, Weiller E.

J Clin Psychiatry. 2015 Jun;76(6):728-34. doi: 10.4088/JCP.13m08827.

13.

A randomized, double-blind, duloxetine-referenced study comparing efficacy and tolerability of 2 fixed doses of vortioxetine in the acute treatment of adults with MDD.

Mahableshwarkar AR, Jacobsen PL, Chen Y, Serenko M, Trivedi MH.

Psychopharmacology (Berl). 2015 Jun;232(12):2061-70. doi: 10.1007/s00213-014-3839-0. Epub 2015 Jan 11.

14.

Treatment-related improvement in neuropsychological functioning in suicidal depressed patients: paroxetine vs. bupropion.

Gorlyn M, Keilp J, Burke A, Oquendo M, Mann JJ, Grunebaum M.

Psychiatry Res. 2015 Feb 28;225(3):407-12. doi: 10.1016/j.psychres.2014.12.004. Epub 2014 Dec 13.

15.

Suicide in stroke survivors: epidemiology and prevention.

Pompili M, Venturini P, Lamis DA, Giordano G, Serafini G, Belvederi Murri M, Amore M, Girardi P.

Drugs Aging. 2015 Jan;32(1):21-9. doi: 10.1007/s40266-014-0233-x. Review.

PMID:
25491561
16.
17.

Social inequalities in suicide: the role of selective serotonin reuptake inhibitors.

Clouston SA, Rubin MS, Colen CG, Link BG.

Am J Epidemiol. 2014 Oct 1;180(7):696-704. doi: 10.1093/aje/kwu191. Epub 2014 Aug 28.

18.

Do serotonin reuptake inhibitors worsen outcome of patients referred to the emergency department for deliberate multi-drug exposure?

Beaune S, Curis E, Casalino E, Juvin P, Mégarbane B.

Basic Clin Pharmacol Toxicol. 2015 Apr;116(4):372-7. doi: 10.1111/bcpt.12311. Epub 2014 Oct 8.

19.

Selective serotonin reuptake inhibitors versus tricyclic antidepressants in young patients: a meta-analysis of efficacy and acceptability.

Qin B, Zhang Y, Zhou X, Cheng P, Liu Y, Chen J, Fu Y, Luo Q, Xie P.

Clin Ther. 2014 Jul 1;36(7):1087-1095.e4. doi: 10.1016/j.clinthera.2014.06.001. Epub 2014 Jul 3. Review.

PMID:
24998011
20.

A double-blind, placebo-controlled study of edivoxetine as an adjunctive treatment for patients with major depressive disorder who are partial responders to selective serotonin reuptake inhibitor treatment.

Ball S, Dellva MA, D'Souza DN, Marangell LB, Russell JM, Goldberger C.

J Affect Disord. 2014;167:215-23. doi: 10.1016/j.jad.2014.06.006. Epub 2014 Jun 14.

PMID:
24995890
Items per page

Supplemental Content

Loading ...
Write to the Help Desk